Cargando…

Treatment landscape and burden of disease in metastatic castration-resistant prostate cancer: systematic and structured literature reviews

PURPOSE: Metastatic castration-resistant prostate cancer (mCRPC) is a lethal disease that imposes a major burden on patients and healthcare systems. Three structured literature reviews (treatment guidelines, treatment landscape, and human/clinical/patient burden) and one systematic literature review...

Descripción completa

Detalles Bibliográficos
Autores principales: Leaning, Darren, Kaur, Gagandeep, Morgans, Alicia K., Ghouse, Ray, Mirante, Osvaldo, Chowdhury, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565658/
https://www.ncbi.nlm.nih.gov/pubmed/37829336
http://dx.doi.org/10.3389/fonc.2023.1240864
_version_ 1785118743015194624
author Leaning, Darren
Kaur, Gagandeep
Morgans, Alicia K.
Ghouse, Ray
Mirante, Osvaldo
Chowdhury, Simon
author_facet Leaning, Darren
Kaur, Gagandeep
Morgans, Alicia K.
Ghouse, Ray
Mirante, Osvaldo
Chowdhury, Simon
author_sort Leaning, Darren
collection PubMed
description PURPOSE: Metastatic castration-resistant prostate cancer (mCRPC) is a lethal disease that imposes a major burden on patients and healthcare systems. Three structured literature reviews (treatment guidelines, treatment landscape, and human/clinical/patient burden) and one systematic literature review (economic burden) were conducted to better understand the disease burden and unmet needs for patients with late-stage mCRPC, for whom optimal treatment options are unclear. METHODS: Embase(®), MEDLINE(®), MEDLINE(®) In-Process, the CENTRAL database (structured and systematic reviews), and the Centre for Reviews and Dissemination database (systematic review only) were searched for English-language records from 2009 to 2021 to identify mCRPC treatment guidelines and studies related to the treatment landscape and the humanistic/economic burden of mCRPC in adult men (aged ≥18 years) of any ethnicity. RESULTS: In total, six records were included for the treatment patterns review, 14 records for humanistic burden, nine records for economic burden, three records (two studies) for efficacy, and eight records for safety. Real-world treatment patterns were broadly aligned with treatment guidelines and provided no optimal treatment sequencing beyond second line other than palliative care. Current post-docetaxel treatments in mCRPC are associated with adverse events that cause relatively high rates of treatment discontinuation or disruption. The humanistic and economic burdens associated with mCRPC are high. CONCLUSION: The findings highlight a lack of treatment options with novel mechanisms of action and more tolerable safety profiles that satisfy a risk-to-benefit ratio aligned with patient needs and preferences for patients with late-stage mCRPC. Treatment approaches that improve survival and health-related quality of life are needed, ideally while simultaneously reducing costs and healthcare resource utilization.
format Online
Article
Text
id pubmed-10565658
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105656582023-10-12 Treatment landscape and burden of disease in metastatic castration-resistant prostate cancer: systematic and structured literature reviews Leaning, Darren Kaur, Gagandeep Morgans, Alicia K. Ghouse, Ray Mirante, Osvaldo Chowdhury, Simon Front Oncol Oncology PURPOSE: Metastatic castration-resistant prostate cancer (mCRPC) is a lethal disease that imposes a major burden on patients and healthcare systems. Three structured literature reviews (treatment guidelines, treatment landscape, and human/clinical/patient burden) and one systematic literature review (economic burden) were conducted to better understand the disease burden and unmet needs for patients with late-stage mCRPC, for whom optimal treatment options are unclear. METHODS: Embase(®), MEDLINE(®), MEDLINE(®) In-Process, the CENTRAL database (structured and systematic reviews), and the Centre for Reviews and Dissemination database (systematic review only) were searched for English-language records from 2009 to 2021 to identify mCRPC treatment guidelines and studies related to the treatment landscape and the humanistic/economic burden of mCRPC in adult men (aged ≥18 years) of any ethnicity. RESULTS: In total, six records were included for the treatment patterns review, 14 records for humanistic burden, nine records for economic burden, three records (two studies) for efficacy, and eight records for safety. Real-world treatment patterns were broadly aligned with treatment guidelines and provided no optimal treatment sequencing beyond second line other than palliative care. Current post-docetaxel treatments in mCRPC are associated with adverse events that cause relatively high rates of treatment discontinuation or disruption. The humanistic and economic burdens associated with mCRPC are high. CONCLUSION: The findings highlight a lack of treatment options with novel mechanisms of action and more tolerable safety profiles that satisfy a risk-to-benefit ratio aligned with patient needs and preferences for patients with late-stage mCRPC. Treatment approaches that improve survival and health-related quality of life are needed, ideally while simultaneously reducing costs and healthcare resource utilization. Frontiers Media S.A. 2023-09-27 /pmc/articles/PMC10565658/ /pubmed/37829336 http://dx.doi.org/10.3389/fonc.2023.1240864 Text en Copyright © 2023 Leaning, Kaur, Morgans, Ghouse, Mirante and Chowdhury https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Leaning, Darren
Kaur, Gagandeep
Morgans, Alicia K.
Ghouse, Ray
Mirante, Osvaldo
Chowdhury, Simon
Treatment landscape and burden of disease in metastatic castration-resistant prostate cancer: systematic and structured literature reviews
title Treatment landscape and burden of disease in metastatic castration-resistant prostate cancer: systematic and structured literature reviews
title_full Treatment landscape and burden of disease in metastatic castration-resistant prostate cancer: systematic and structured literature reviews
title_fullStr Treatment landscape and burden of disease in metastatic castration-resistant prostate cancer: systematic and structured literature reviews
title_full_unstemmed Treatment landscape and burden of disease in metastatic castration-resistant prostate cancer: systematic and structured literature reviews
title_short Treatment landscape and burden of disease in metastatic castration-resistant prostate cancer: systematic and structured literature reviews
title_sort treatment landscape and burden of disease in metastatic castration-resistant prostate cancer: systematic and structured literature reviews
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565658/
https://www.ncbi.nlm.nih.gov/pubmed/37829336
http://dx.doi.org/10.3389/fonc.2023.1240864
work_keys_str_mv AT leaningdarren treatmentlandscapeandburdenofdiseaseinmetastaticcastrationresistantprostatecancersystematicandstructuredliteraturereviews
AT kaurgagandeep treatmentlandscapeandburdenofdiseaseinmetastaticcastrationresistantprostatecancersystematicandstructuredliteraturereviews
AT morgansaliciak treatmentlandscapeandburdenofdiseaseinmetastaticcastrationresistantprostatecancersystematicandstructuredliteraturereviews
AT ghouseray treatmentlandscapeandburdenofdiseaseinmetastaticcastrationresistantprostatecancersystematicandstructuredliteraturereviews
AT miranteosvaldo treatmentlandscapeandburdenofdiseaseinmetastaticcastrationresistantprostatecancersystematicandstructuredliteraturereviews
AT chowdhurysimon treatmentlandscapeandburdenofdiseaseinmetastaticcastrationresistantprostatecancersystematicandstructuredliteraturereviews